Immune markers for monitoring the progression of autoimmune disease

Diabetes/Metabolism Research and Reviews

Volumn 15, Issue 2, 1999, Pages 141-145

  Schloot, Nanette C ^a   Pozzilli, Paolo ^b   Mandrup Poulsen, Thomas ^c  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

Autoimmune; Markers; Monitoring; Surrogate

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; INTERLEUKIN 2; N ACETYLASPARTIC ACID; TECHNETIUM 99M;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DISEASE COURSE; ENTERITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSPLANTATION;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MULTIPLE SCLEROSIS; TRANSPLANTATION IMMUNOLOGY; WORLD HEALTH;

EID: 0033015326     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(199903/04)15:2<141::AID-DMRR19>3.0.CO;2-A     Document Type: Review

References (26)

1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436.
2. Brandtzaeg P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997; 18; 555-589.
3. Hartung HP. Immune mediated demyelination. Ann Neurol 1993; 33: 563-567.
4. Poser CM. Notes on the pathogenesis of multiple sclerosis. Clin Neurosci 1994; 2: 258-265.
5. Giovannoni G, Kiesgeier B, Hartung HP. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64 (suppl 1): S31-S36.
6. Erickson BJ, Noseworthy JH. Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies. Mayo Clin Proc 1997; 72: 1080-1089.
7. McCutcheon M, Wehner N, Wensky A, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210: 149-166.
8. Giovannoni G, Lai M, Kidd D, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997; 120: 1-13.
9. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996; 31 (suppl 216): 149-159.
10. Kern F, Ode-Hakim S, Nugel H, Vogt K, Volk HD, Reinke P. Peripheral T cell activation in long term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription. J Am Soc Nephrol 1996; 7: 2476-2482.
11. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998; 4: 975-978.
12. Petersen JS, Dyrberg T, Karlsen AE, et al. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Diabetes 1994; 43: 1291-1296.
13. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46: 1701-1710.
14. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS and participating laboratories. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes. Diabetes 1998; 47: 1857-1866.
15. Naserke HE, Lampasonea V, Ziegler AG, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998; 161: 6963-6969.
16. Karvonen M, Rusanen J, Sundberg M, et al. Regional differences in the incidence of insulin-dependent diabetes mellitus among children in Finland from 1987 to 1991. Childhood Diabetes in Finland (DiMe) Study Group. Ann Med 1997; 29: 297-304.
17. Coutant R, Landais P, Rosilio M, et al. Low dose linomide in Type 1 juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998; 41: 1040-1046.
18. Atkinson MA, Kaufman DL, Campbell L, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992; 339: 458-459.
19. Roep BO. Perspectives in diabetes: T-cell responses to islet autoantigens in insulin-dependent diabetes mellitus: the search for the Holy Grail. Diabetes 1996; 45: 1147-1156.
20. Schloot NC, Roep BO, Wegmann D, et al. Altered immune response to insulin in newly diagnosed versus insulin treated patients and healthy control subjects. Diabetologia 1997; 40: 564-572.
21. Signore A, Parman A, Pozzilli P, Andreani D, Beverly PCL. Detection of activated lymphocytes in endocrine pancreas of BB/ W rats by injection of 1231-labelled interleukin-2: an early sign of type 1 diabetes. Lancet 1987; 2: 537-540.
22. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of Technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997; 24: 579-586.
23. Roep BO, Stobbe I, Duinkerken G, et al Auto- and alloimmune reactivity to human islet allografts transplanted to insulin-dependent diabetes mellitus patients. Diabetes 1999; 48: 484-490.
24. Signore A, Chianelli M, Maiuri L, et al. Imaging of autoimmune phenomena in patients with coeliac disease and associated neurological disorders. In Epilepsy and Other Neurological Disorders in Coeliac Disease, Gobbi G (ed). John Libbey & Company Ltd, 1997; 151-157.
25. Chianelli M, Mather SJ, Martin-Comin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 1997; 18: 437-455.
26. Olmos P, A' Hern E, Heaton DA, et al. The significance of the concordance rate for type 1 (insulin dependent) diabetes in identical twins. Diabetologia 1988; 31: 747-750.